DAX22.391 -0,7%ESt505.304 -0,3%Top 10 Crypto12,09 -0,5%Dow42.225 +0,6%Nas17.601 +0,9%Bitcoin76.543 +1,1%Euro1,0918 +0,8%Öl73,25 -0,2%Gold3.147 +0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 RENK RENK73 thyssenkrupp 750000 Novo Nordisk A3EU6F Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 Bayer BAY001 HENSOLDT HAG000 Volkswagen (VW) vz. 766403 Commerzbank CBK100 Amazon 906866 Deutsche Telekom 555750 Siemens Energy ENER6Y
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Dow letztlich im Plus -- DAX schließt tiefer -- Tesla: Auslieferungen in Q1 gefallen -- Trump kündigt neues weitreichendes Zollpaket an - Rheinmetall, CoreWeave, Palantir im Fokus
Top News
Software-Aktien unter Druck: "DOGE" und KI-Zweifel belasten - ist jetzt der richtige Zeitpunkt für den Wiedereinstieg? Software-Aktien unter Druck: "DOGE" und KI-Zweifel belasten - ist jetzt der richtige Zeitpunkt für den Wiedereinstieg?
NBA-Star: Deshalb sind Kryptowährungen der Schlüssel zur finanziellen Freiheit NBA-Star: Deshalb sind Kryptowährungen der Schlüssel zur finanziellen Freiheit
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Hemispherx Biopharma Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
0,1000 EUR -0,0160 EUR -13,79 %
STU
0,1210 USD -0,0063 USD -4,95 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.8,29 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PREX

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00901B1052

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAIM

Hemispherx Biopharma Aktien News

DatumMeistgelesen
PR NewswireAIMIA ANNOUNCES EXECUTIVE SUCCESSION PLAN AND BOARD TRANSITION
PR NewswireAIMIA TO REPORT FOURTH QUARTER AND FULL-YEAR 2024 RESULTS ON MARCH 28
GlobeNewswireAIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Wer­bungHemispherx Biopharma-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireAIMIA PROVIDES NOTICE OF SERIES 1 PREFERRED SHARES REDEMPTION RIGHT AND RESET OF DIVIDEND RATE
PR NewswireAIMIA ANNOUNCES PRELIMINARY RESULTS OF ITS SUBSTANTIAL ISSUER BID
PR NewswireAIMIA EXTENDS EXPIRY DATE OF ITS SUBSTANTIAL ISSUER BID
PR NewswireAIMIA PROVIDES REMINDER OF UPCOMING EXPIRATION OF SUBSTANTIAL ISSUER BID
GlobeNewswireAIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
PR NewswireAIMIA DECLARES PREFERRED SHARE DIVIDENDS
PR NewswireAIMIA REPORTS STRONG THIRD QUARTER 2024 RESULTS AND REITERATES 2024 GUIDANCE
PR NewswireAIMIA AND MITHAQ SIGN COOPERATION AGREEMENT
PR NewswireAIMIA TO REPORT THIRD QUARTER 2024 RESULTS ON NOVEMBER 8
GlobeNewswireAIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
PR NewswireAIMIA DECLARES PREFERRED SHARE DIVIDENDS
PR NewswireAIMIA REPORTS SOLID SECOND QUARTER 2024 RESULTS, REITERATES GUIDANCE, AND OUTLINES NEAR-TERM PRIORITIES FOR VALUE CREATION
PR NewswireAIMIA TO REPORT SECOND QUARTER 2024 RESULTS ON AUGUST 13
PR NewswireAIMIA COMPLETES COMMON SHARE REPURCHASE
PR NewswireAIMIA ENTERS INTO A PRIVATE AGREEMENT WITH MILKWOOD CAPITAL (UK) LTD. TO REPURCHASE COMMON SHARES
PR NewswireAIMIA ANNOUNCES LEADERSHIP APPOINTMENTS DESIGNED TO ACCELERATE ITS STRATEGY FOR UNLOCKING SHAREHOLDER VALUE
PR NewswireAIMIA CONFIRMS ELECTION OF DIRECTORS
PR NewswireAIMIA CONFIRMS ELECTION OF DIRECTORS
PR NewswireLAST CHANCE FOR AIMIA SHAREHOLDERS TO MAKE THEIR VOTE COUNT
PR NewswireAIMIA RELEASES VIDEO ON STRATEGIC ACTIONS AND UNLOCKING SHAREHOLDER VALUE; REMINDS SHAREHOLDERS TO VOTE AHEAD OF DEADLINE
PR NewswireLEADING PROXY ADVISOR ISS RECOMMENDS AIMIA SHAREHOLDERS TO VOTE FOR ALL MANAGEMENT NOMINEES
PR NewswireMithaq Warns Aimia Shareholders of Potential for Board Misconduct at Upcoming Annual General Meeting
PR NewswireAIMIA APPOINTS JAMES SCARLETT TO BOARD OF DIRECTORS
PR NewswireMithaq Files Proxy Circular and Sends Letter to Aimia Shareholders
PR NewswireAIMIA CONFIRMS THE LAUNCH OF ITS NORMAL COURSE ISSUER BID TO REPURCHASE UP TO 7,009,622 SHARES
PR NewswireAIMIA PROVIDES RESPONSE TO MITHAQ'S STATEMENTS REGARDING UPCOMING ANNUAL MEETING OF SHAREHOLDERS
PR NewswireAIMIA FILES INFORMATION CIRCULAR, ANNOUNCES PROPOSED DIRECTOR NOMINEES, AND ISSUES LETTER TO SHAREHOLDERS
PR NewswireAIMIA ANNOUNCES INTENTION TO LAUNCH NORMAL COURSE ISSUER BID
PR NewswireAIMIA CONFIRMS $32.9 MILLION RECEIPT OF EARN-OUT FROM PLM TRANSACTION
PR NewswireAIMIA ANNOUNCES TERMINATION OF PALADIN AGREEMENTS
PR NewswireAIMIA DECLARES PREFERRED SHARE DIVIDENDS
PR NewswireAIMIA REPORTS STRONG FIRST QUARTER 2024 RESULTS, SETS PRIORITIES TO CREATE VALUE, AND PROVIDES GUIDANCE
GlobeNewswireAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
GlobeNewswireAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
PR NewswireAIMIA TO REPORT FIRST QUARTER 2024 RESULTS ON MAY 15
GlobeNewswireAIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
GlobeNewswireAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Wer­bung

Hemispherx Biopharma News

Hemispherx Biopharma News: auf dieser Seite finden Sie alle Hemispherx Biopharma News und Nachrichten zur Hemispherx Biopharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Hemispherx Biopharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Hemispherx Biopharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.